Page last updated: 2024-09-04

vatalanib and Dermatitis, Allergic Contact

vatalanib has been researched along with Dermatitis, Allergic Contact in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Iijima, M; Nakanishi, T; Sueki, H; Watanabe, H; Yamamoto, A; Yasuhara, H1

Other Studies

1 other study(ies) available for vatalanib and Dermatitis, Allergic Contact

ArticleYear
Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
    The Journal of dermatology, 2007, Volume: 34, Issue:7

    Topics: Animals; Antigens, CD; Cell Migration Inhibition; Dermatitis, Allergic Contact; Dermis; Ear, External; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescein-5-isothiocyanate; Langerhans Cells; Laser-Doppler Flowmetry; Lymph Nodes; Mice; Mice, Inbred BALB C; Oxazolone; Phthalazines; Protein Kinase Inhibitors; Pyridines; Skin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2

2007